Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Tandem Diabetes' Q1 Bottom-Line Slide Deeper Into Red Despite Sales Growth

  • Tandem Diabetes Care Inc (NASDAQ:TNDMposted Q1 losses of $(0.23) deeper than $(0.08) posted a year ago and missing the consensus of $(0.07).
  • Sales increased 25% to $175.91 million, beating the consensus of $168.43 million.
  • Worldwide pump shipments increased 11% Y/Y to 28,095.
  • The gross margin remained almost unchanged at 52%.
  • The company reported an operating loss of $(15.34) million, compared to $(3.24) million.
  • Tandem Diabetes ended Q1 with cash and equivalents of $635.4 million.
  • Guidance: Tandem expects FY22 revenues of $850 million - $865 million, reflecting Y/Y growth of 21% - 23%, versus the consensus of $846.54 million.
  • Earlier, the company estimated sales of $845 million - $860 million.
  • It expects gross margin to be 54% and Adjusted EBITDA margin to be 14% - 15%.
  • Price Action: TNDM shares traded lower by 12.2% at $82.90 on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.